TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11297577
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment for 18 months
Study: 11297577
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 18 months
Study: 9173675
Drug: Cerebrolysin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cerebrolysin infusion (20 ml in 500 ml Ringer) for 10 days
Study: 9173675
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin B infusion 5 ml vitamin B complex in 500 ml Ringer) for 10 days
Study: 31518023
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g CSO per ton
Study: 31518023
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g CSO per ton
Study: 31518023
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g CSO per ton)
Study: 22390572
Drug: Heparin 100
Normalized name: heparin 100 units/mL injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 100 U/mL
Study: 18328639
Drug: Phentermine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine (60 mg)
Study: 8686349
Drug: Olsalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine (2 x 2 capsules of 250 mg)
Study: 8686349
Drug: Mesalazine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (3 x 2 tablets of 250 mg)
Study: 1906745
Drug: OKT3 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OKT3 therapy for immunosuppression
Study: 27096623
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg·kg‐1)
Study: 31852124
Drug: Drug +
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug + diet group
Study: 16549954
Drug: Drug group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug group
Study: 30027003
Drug: Cetirizine 10‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10‐mg once daily in the morning (QAM)
Study: 30027003
Drug: Cetirizine 10‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10‐mg once daily at bedtime (QHS)
Study: 30027003
Drug: Cetirizine 5‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5‐mg twice daily
Study: 30027003
Drug: Cetirizine 5‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5‐mg QAM
Study: 30027003
Drug: Cetirizine 10‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10‐mg QHS
Study: 30027003
Drug: Chlorpheniramine 8‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 8‐mg BID
Study: 25081694
Drug: Beta glucan
Normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta glucan (two 10-mg capsules daily for 21 days)
Study: 25081694
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules daily for 21 days)
Study: 19434781
Drug: Emerging therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging therapies targeting immune-mediated disease mechanisms
Study: 19434781
Drug: Emerging therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging therapies targeting distinct cell types and mechanisms
Study: 14998579
Drug: Nimodipine tablets
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine tablets with pH 4.5 acetate buffer containing 0.3% SDS
Study: 14998579
Drug: Two brands
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two brands of nimodipine tablets
Study: 12865102
Drug: Albuterol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (10 mg)
Study: 22968823
Drug: Subconjunctival triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival triamcinolone injection
Study: 30553026
Drug: Moderate exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate exercise intensity group (MG)
Study: 26141208
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination of EGFR-TKI and chemotherapy
Study: 26141208
Drug: No post-study
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No post-study treatments
Study: 15478384
Drug: AeroChamber (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AeroChamber (200 microg of budesonide twice daily)
Study: 11137829
Drug: Nisoldipine 40
Normalized name: nisoldipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 40 mg
Study: 9537937
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin (INR 2 to 3)
Study: 9537937
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin (INR 1.2 to 1.5) plus aspirin (325 mg/d)
Study: 9537937
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (low-intensity warfarin plus aspirin)
Study: 26647766
Drug: Self-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment group (STG)
Study: 15811142
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg three times daily)
Study: 1691134
Drug: High-dose Ara-C
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose Ara-C (3 g/m2 i.v. q 12 h days 1-4) and m-AMSA (120 mg/m2 i.v. day 5) for consolidation
Study: 11835723
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine treatment)
Study: 26511605
Drug: EPICENTER care
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPICENTER care (multi-component treatment package including cognitive behavioral therapy, family psychoeducation, and metacognitive remediation)
Study: 23227811
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets during the spring camp
Study: 15522983
Drug: Pharmacist involvement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist involvement in treatment
Study: 12152676
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral vitamin K
Study: 12017373
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg b.i.d.
Study: 10433575
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg b.i.d.
Study: 8131017
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine gel (10 ml intraurethrally)
Study: 8131017
Drug: Plain lubricating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain lubricating gel (10 ml)
Study: 88708
Drug: Midodrine (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (0.06 mg/kg/dose)
Study: 22595386
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (4 g daily for 8 weeks)
Study: 15214098
Drug: Reminiscence intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reminiscence intervention (weekly sessions)
Study: 2634614
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms L-T3 (Thyrotardin)
Study: 30475232
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous amisulpride
Study: 27618796
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous amisulpride
Study: 22278628
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (8-12 mg once daily by forced titration)
Study: 22278628
Drug: Azilsartan (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan (20-40 mg once daily by forced titration)
Study: 18091641
Drug: 150 microg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg/m2 G‐CSF bis in die subcutaneously (from day 0 to day 4) in addition to standard care
Study: 9528717
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution 200 mg/day for 14 days
Study: 9528717
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution 200 mg/day for 7 days
Study: 9528717
Drug: Fluconazole tablets
Normalized name: Fluconazole Tablets
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole tablets 100 mg/day for 14 days
Study: 7629001
Drug: Midaglizole (MID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole (MID) 300 mg/day for 1 week
Study: 7629001
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (asthmatics not taking beta 2‐agonists)
Study: 2930674
Drug: i.v. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketamine 2 mg kg‐1 followed by an infusion of 2 mg kg‐1 h‐1
Study: 25644122
Drug: Multiple intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intravenous doses of 2.0 g cefozopran every 12 h for 4 days
Study: 24219348
Drug: Renin angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin angiotensin system agents
Study: 21255253
Drug: Episodic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic therapy with ≥25 IU kg(‐1) every 12‐24 h until complete clinical bleeding resolution
Study: 17609623
Drug: Episodic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic therapy
Study: 17396216
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (approximately 10 g/day over three months)
Study: 12925827
Drug: Air-abrasion and
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-abrasion and Carisolv gel
Study: 11037756
Drug: Water (control;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (control; treatment A)
Study: 9259871
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of nifedipine at 0.65 mg/h
Study: 9259871
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of nifedipine at 1.25 mg/h
Study: 27147900
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (80 mg/m²)
Study: 29595562
Drug: Ramelteon (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon (8 mg/d)
Study: 20856164
Drug: JE-CV vaccine
Normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV vaccine (≥4 log10 plaque forming units) administered 1 month before or after hepatitis A control vaccine
Study: 19035877
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg inhaled salbutamol via spacer device
Study: 30242825
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg nebulized salbutamol
Study: 7612060
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine bid
Study: 16887123
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg extended-release niacin (n=20)
Study: 15080372
Drug: Daily indapamide
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily indapamide (1 mg)
Study: 15080372
Drug: Every other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every other day indapamide (1 mg)
Study: 11841931
Drug: 5-FU/leucovorin (5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/leucovorin (5-FU 425 mg/m2 plus leucovorin 20 mg/m2 days 1-5, every 4 weeks)
Study: 7926082
Drug: GnRH‐agonist (GnRH‐a)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐agonist (GnRH‐a) treatment
Study: 28139830
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (100 mg/day for 7 days)
Study: 25888250
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 5,000 IU/dose, subcutaneously administered at 48 hours and 72 hours after acute IS
Study: 11297242
Drug: UFT (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (2 x 100 mg capsules) and leucovorin (2 x 15 mg tablets) administered after an overnight fast
Study: 11297242
Drug: UFT (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (2 x 100 mg capsules) and leucovorin (2 x 15 mg tablets) administered 5 min after a high‐fat meal
Study: 9259247
Drug: Oral pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pamidronate (APD)
Study: 8512628
Drug: Milacemide 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide 1200 mg/day
Study: 8512628
Drug: Milacemide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide (all doses combined)
Study: 28566022
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment
Study: 20132152
Drug: 4 mg/day
Normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/day irsogladine maleate (n = 150)
Study: 14527077
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline spray for 8 weeks
Study: 14527077
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal corticosteroids for 4 weeks followed by placebo saline spray for 4 weeks
Study: 14527077
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline spray for 4 weeks followed by topical nasal corticosteroids for 4 weeks
Study: 4056254
Drug: Theobromine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobromine (10 mg/kg)
Study: 7130553
Drug: Theophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5 mg/kg)
Study: 29791287
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (anthracycline and taxane) without bevacizumab
Study: 20429895
Drug: Yoga plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga plus Cognitive Behavioral Therapy (CBT) smoking cessation intervention
Study: 20429895
Drug: Wellness program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wellness program plus Cognitive Behavioral Therapy (CBT) smoking cessation intervention
Study: 10795592
Drug: 1.9 Lf
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.9 Lf tetanus toxoid (0.25 ml)
Study: 10795592
Drug: 3.75 Lf
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 Lf tetanus toxoid (0.5 ml)
Study: 6502941
Drug: L-carnitine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (900 mg, p.o. daily)
Study: 18837470
Drug: Pol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pol + BG (5 g beta-glucan)
Study: 16084463
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg intrarectal lidocaine jelly
Study: 1687485
Drug: Savoxepine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savoxepine (0.5 mg)
Study: 1687485
Drug: Chlorpromazine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (75 mg)
Study: 1687485
Drug: Savoxepine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savoxepine (average 0.1 to 0.9 mg/d) in clinical trials
Study: 27769289
Drug: Oily fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily fish consumption (300 g/week)
Study: 11165126
Drug: Mistletoe extract
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe extract treatment
Study: 17980250
Drug: AZD6140 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6140 90 mg
Study: 17980250
Drug: AZD6140 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6140 180 mg
Study: 17980250
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg loading dose plus 75 mg once daily
Study: 15745385
Drug: Inhaled tiotropium
Normalized name: tiotropium Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tiotropium bromide 18 microg
Study: 15745385
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Placebo
Study: 12479050
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg daily for four weeks
Study: 7036285
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (Control)
Study: 9469330
Drug: Perioperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative treatment with one course of FAC
Study: 18219837
Drug: Fexofenadine hydrochloride,
Normalized name: Fexofenadine Hydrochloride, 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride, 15 mg, twice daily for 8 days
Study: 18219837
Drug: Fexofenadine hydrochloride,
Normalized name: Fexofenadine Hydrochloride, 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride, 30 mg, twice daily for 8 days
Study: 18219837
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 8 days
Study: 14742305
Drug: Pranlukast 300
Normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pranlukast 300 mg twice a day
Study: 11549425
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 450 mg/m2 plus levamisol (B)
Study: 21850019
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream
Study: 9449906
Drug: 1% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% imiquimod cream
Study: 10085475
Drug: Vehicle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle treatment
Study: 26125735
Drug: 3D‐CRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D‐CRT + docetaxel (36 mg/m(2) once weekly for 6 weeks) + adjuvant chemotherapy
Study: 26125735
Drug: 3D‐CRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D‐CRT + docetaxel + adjuvant chemotherapy
Study: 20934206
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for 3 years
Study: 20934206
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for 4 years
Study: 19205289
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for 5 years
Study: 12677456
Drug: Electrical Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Stimulation Therapy (EST)
Study: 12677456
Drug: Biofeedback Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback Therapy (BFT)
Study: 27599667
Drug: telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 80 mg
Study: 12814476
Drug: FTY720 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 (0.25 to 3.5 mg)
Study: 6446445
Drug: Aspirin (3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3600 mg)
Study: 6446445
Drug: Phenylbutazone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (300 mg)
Study: 10909992
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg)
Study: 27808418
Drug: Lamotrigine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (300 mg)
Study: 27808418
Drug: Levetiracetam (3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (3,000 mg)
Study: 15105061
Drug: NuvaRing (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuvaRing (15 microg ethinylestradiol and 120 microg etonogestrel daily)
Study: 15105061
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (30 microg ethinylestradiol and 150 microg levonorgestrel)
Study: 8964329
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 500 mg Q8 hours for 10 doses followed by oral prednisone for two weeks and tapering doses thereafter
Study: 8964329
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone one mg per kilogram of body weight for two weeks followed by tapering doses
Study: 31785587
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OXT; 6 IU, 12 IU, 24 IU)
Study: 28679021
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of oxytocin (10 IU)
Study: 28679021
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of oxytocin (100 or 400 IU)
Study: 28679021
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of oxytocin
Study: 26355232
Drug: Aflibercept in
Normalized name: aflibercept Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept in combination with mFOLFOX6
Study: 23002282
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with pertuzumab (arm A, n=74)
Study: 23002282
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (arm B, n=75)